EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Purifying Bevacizumab via Affinity Precipitation Using Branched Peptide

Joaquin Amir Eloy, Jésica Ayelén Rodríguez, Gabriela Romina Barredo-Vacchelli, Magalí Sol García-Cabanas, Débora Eugenia Rinaldi, Barbara Richichi, Marco Marradi, Silvia Andrea Camperi

Journal of Pharmaceutical and BioTech Industry · 28.07.2026 · 3 (3) · 18

DOI: 10.3390/jpbi3030018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, online erschienen am 28.07.2026. Verfasst von Joaquin Amir Eloy und 7 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic monoclonal antibody bevacizumab is typically purified using protein A affinity chromatography, a highly effective but costly method. Affinity-based precipitation for antibody purification is a lower-cost approach. In this work, a precipitation protocol was developed for bevacizumab purification using a branched peptide (Ac-PHQGQHIG-Ahx3)2-K-Ahx3-PHQGQHIG-NH2, which contains the epitope PHQGQHIG that is responsible for interacting with bevacizumab. The peptide was synthesised by a microwave-assisted solid-phase peptide method, employing LiCl as an additive to prevent aggregation and ensure high purity and yield. Three molecules of 6-aminohexanoic acid were introduced between each epitope branch as spacer arms to promote the formation of cyclic complexes. Bevacizumab purification from cell-free culture broth was achieved through a fractional precipitation process. First, a negative precipitation step using (NH4)2SO4 1.18 M was performed to remove contaminants. Afterwards, 5 moles of peptide per mol of bevacizumab was added to the supernatant, together with additional (NH4)2SO4, to reach a final concentration of 1.20 M. Under these conditions, bevacizumab was recovered in the precipitate with 98% purity and a yield of 73%. In addition to being recyclable, the peptide’s relatively low production cost could enable the development of a single-use purification process, which would be particularly advantageous for biopharmaceutical manufacturing.

Zitieren

APA

Eloy, J. A., Rodríguez, J. A., Barredo-Vacchelli, G. R., García-Cabanas, M. S., Rinaldi, D. E., Richichi, B., Marradi, M., & Camperi, S. A. (2026). Purifying Bevacizumab via Affinity Precipitation Using Branched Peptide. Journal of Pharmaceutical and BioTech Industry, 3(3), 18. https://doi.org/10.3390/jpbi3030018

Vancouver

Eloy JA, Rodríguez JA, Barredo-Vacchelli GR, García-Cabanas MS, Rinaldi DE, Richichi B, et al. Purifying Bevacizumab via Affinity Precipitation Using Branched Peptide. Journal of Pharmaceutical and BioTech Industry. 2026;3(3):18. doi:10.3390/jpbi3030018

BibTeX
@article{Eloy2026,
  author = {Eloy, Joaquin Amir and Rodríguez, Jésica Ayelén and Barredo-Vacchelli, Gabriela Romina and García-Cabanas, Magalí Sol and Rinaldi, Débora Eugenia and Richichi, Barbara and Marradi, Marco and Camperi, Silvia Andrea},
  title = {Purifying Bevacizumab via Affinity Precipitation Using Branched Peptide},
  journal = {Journal of Pharmaceutical and BioTech Industry},
  year = {2026},
  volume = {3},
  number = {3},
  pages = {18},
  doi = {10.3390/jpbi3030018}
}
Kostenlos starten →